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Aim of database: To monitor the development of diabetic eye disease in Denmark and to 
evaluate the accessibility and effectiveness of diabetic eye screening programs with focus on 
interregional variations. 
Target population: The target population includes all patients diagnosed with diabetes. 
 Denmark (5.5 million inhabitants) has ~320,000 diabetes patients with an annual increase 
of 27,000 newly diagnosed patients. The Danish Registry of Diabetic Retinopathy (DiaBase) 
 collects data on all diabetes patients aged ≥18 years who attend screening for diabetic eye disease 
in hospital eye departments and in private ophthalmological practice. In 2014–2015, DiaBase 
included data collected from 77,968 diabetes patients.
Main variables: The main variables provide data for calculation of performance indicators to 
monitor the quality of diabetic eye screening and development of diabetic retinopathy. Data with 
respect to age, sex, best corrected visual acuity, screening frequency, grading of diabetic retinopa-
thy and maculopathy at each visit, progression/regression of diabetic eye disease, and prevalence of 
blindness were obtained. Data analysis from DiaBase’s latest annual report (2014–2015) indicates 
that the prevalence of no diabetic retinopathy, nonproliferative  diabetic retinopathy, and prolifera-
tive diabetic retinopathy is 78%, 18%, and 4%, respectively. The percentage of patients without 
diabetic maculopathy is 97%. The proportion of patients with regression of diabetic retinopathy 
(20%) is greater than the proportion of patients with  progression of diabetic retinopathy (10%).
Conclusion: The collection of data from diabetic eye screening is still expanding in Denmark. 
Analysis of the data collected during the period 2014–2015 reveals an overall decrease of diabetic 
retinopathy compared to the previous year, although the number of patients newly diagnosed 
with diabetes has been increasing in Denmark. DiaBase is a useful tool to observe the quality 
of screening, prevalence, and progression/regression of diabetic eye disease. 
Keywords: diabetes, DiaBase, Danish Diabetes Database, national annual report, quality of 
care, database, registry, quality indicator
Introduction
Diabetic retinopathy is the most common complication in diabetes.1,2 It is a chronic, 
progressive, potentially sight-threatening disease of the retinal microvasculature 
that is associated with prolonged hyperglycemia and other conditions linked to 
diabetes mellitus such as hypertension.3 The threat to sight is due to either growth 
of new vessels leading to intraocular hemorrhage and possible retinal detachment 
with profound sight loss or localized damage to the macula of the eye with loss of 
central visual acuity.3
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Grading of diabetic retinopathy is based on visible signs 
of increasing severity on ophthalmoscopy and on imag-
ing. Diabetic retinopathy is classified as proliferative or 
nonproliferative (background/preproliferative) retinopathy 
based on the presence or absence of abnormal new vessels, 
respectively. 
Subgroups of nonproliferative diabetic retinopathy 
(mild, moderate, preproliferative) reflect increasing severity 
of the disease, which consequently results in shortening of 
screening intervals.4 Nonproliferative diabetic retinopathy is 
typically managed by optimizing the patient’s general health. 
Treatment of proliferative diabetic retinopathy comprises 
panretinal photocoagulation. It is hypothesized that this 
technique reduces the amount of ischemic retina, and thus 
the production of angiogenic molecules.
Retinopathy affecting the macula is separately described 
as diabetic maculopathy. Diabetic maculopathy is a leading 
cause of visual loss in diabetic retinopathy. It usually affects 
older, noninsulin-dependent diabetes patients. Diabetic 
maculopathy is divided into three types, based on whether 
it causes focal, ischemic or diffuse edema, and may include 
tractional (vitreoretinal) or nontractional (intraretinal) com-
ponents.3 The management of diabetic macular edema has 
advanced significantly with the introduction of anti-VEGF 
(vascular endothelial growth factor) treatments.3 However, 
macular laser treatment still plays a major role in treating 
noncenter-involving macular edema.5
Vision loss due to diabetic retinopathy is one of the 
leading causes of visual loss worldwide and is an important 
cause of impaired vision and disability in the working-age 
population.6,7,8 Advanced diabetic eye disease has a negative 
influence on quality of life.6 Therefore, eye screening for the 
diabetes population aims to identify patients with early signs 
of sight-threatening disease to facilitate efficient treatment 
and prevent loss of sight.
Aim of database
The Danish Registry of Diabetic Retinopathy (DiaBase) 
was established to monitor the development of diabetic eye 
disease in Denmark and to evaluate the accessibility and 
effectiveness of diabetic eye screening programs with focus 
on interregional variations.9 The main aim of the registry 
is to enable evaluation of quality of care for patients with 
diabetic eye disease.
Target population
The target population includes all patients diagnosed with 
diabetes in Denmark. At present, Denmark (5.5  million 
 inhabitants) has ~320,000 diabetes patients with an annual 
increase of ~27,000 newly diagnosed patients.10 The preva-
lence of diabetes in Denmark has more than doubled since 
1996 and was 5737 per 100,000 people in 2012.10 DiaBase 
contains data on all diabetes patients aged ≥18 years who 
attend screening for diabetic eye disease in the five regions 
of Denmark. Eye examination of children with diabetes is 
recorded in the Children Diabetes Registry (DanDiabKids 
[children and teenagers with diabetes <18 years old]). In 
2011, the Adult Diabetes Registry (adult patients with dia-
betes from 18 years old), the DiaBase, and the DanDiabKids 
joined to form the Danish Diabetes Database.9
DiaBase receives data collected from hospital eye depart-
ments and private ophthalmological practices where diabetes 
patients aged ≥18 years attend diabetic eye screening. In 
Denmark, diabetes care is managed by both primary care 
physicians in private practice and hospital-based endocrinolo-
gists. Diabetic eye screening for most patients attending their 
primary care physician is delivered by an ophthalmologist 
in private practice. Patients being followed in endocrinology 
departments receive diabetic eye screening in the eye depart-
ment of the respective hospital. Data from each screening 
visit are collected and sent electronically to DiaBase. An 
annual report analyzing diabetes screening data from the 
previous year is issued every spring by the steering commit-
tee. National guidelines, based on international guidelines,3,5 
determine screening intervals and treatment protocols. 
DiaBase was established between 2003 and 2006 and is 
still in the development process. The systematic collection 
of outpatient data from hospitals in Denmark started in 2007 
and was extended nationwide in 2010. Data collection on 
patients screened by ophthalmologists in private practice 
started in 2013. In 2014–2015, the Registry included data 
from 77,968 diabetes patients;11 of these patients, 57,985 
had been screened by ophthalmologists in private practice, 
whereas 20,291 patients had been screened in hospitals.11 
Main variables
Key quality indicators for DiaBase were selected according 
to international standards for good clinical practice: two 
process indicators to examine efficiency and three perfor-
mance indicators to examine outcome9 (Table 1). Indicator 
measurements are based on the collection of data with regard 
to the following main variables:9
•	 Registering screening unit 
•	 Patient name and unique Danish identification number
•	 Date of screening visit
•	 Indication for screening
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•	 Previous eye surgery
•	 Best corrected visual acuity
•	 Screening method (slit lamp examination or retinal 
photography)
•	 Diabetic retinopathy and maculopathy grading according 
to Wilkinson et al12
•	 Quality of screening photograph
•	 Definition of next examination (screening, treatment)
•	 Interval to next screening visit.
The data on diabetes type and duration of disease are 
recorded in The Adult Diabetes Registry. 
Follow-up
A DiaBase report containing calculations of the key indi-
cators is published every year. At annual meetings, data 
issues, interregional variations, and definition of indicators 
are discussed among representatives from each region. 
Descriptive data analysis from DiaBase 
annual report 2014–2015
Patient classification
DiaBase identifies patients with newly diagnosed macu-
lopathy as “diabetic maculopathy, newly diagnosed”. In 
case of treatment for diabetic eye disease, screening is 
temporarily discontinued. After completion of treatment, 
patients re-enter regular diabetic eye screening and are 
described as “resumed routine screening”.9 Patients with 
treated diabetic maculopathy are recorded in the category 
“treated maculopathy, stable”. If maculopathy recurs, 
requiring additional treatment, patients are classified as 
“treated maculopathy, recurrence”. The same system applies 
to diabetic retinopathy. DiaBase classifies treated patients as 
“laser-treated proliferative diabetic retinopathy, stable”. In 
case of relapse requiring additional laser treatment, patients 
are labeled “laser-treated proliferative diabetic retinopathy, 
recurrence”.
Frequency of eye screening
Until 2013, this indicator measured the proportion of diabetes 
patients who received eye screening at least every 2 years. How-
ever, the interval for screening visits should be tailored to the 
severity of disease.4,5 To provide the basis for individualized eye 
screening intervals, the definition of this indicator was changed 
to measure the proportion of patients who were screened within 
the defined time interval (Table 2). This ultimately measures 
access to screening for diabetes patients. Neither hospital eye 
departments nor ophthalmologists in private practice met the 
standard for this variable (at least 90% of patients should obtain 
eye screening within the defined interval). As this is the first 
year, this indicator is calculated in its altered state, the amount 
of data collected is still insufficient to provide a proper analysis.
Prevalence of diabetic retinopathy and maculopathy
The nationwide prevalence of nonproliferative diabetic reti-
nopathy is 18%, with 47% of patients screened in hospitals 
and 14% by ophthalmologists in private practice (Table 3). 
Mild nonproliferative diabetic retinopathy alone contributes 
to 13%, while 78% of diabetes patients do not have dia-
betic retinopathy. However, there are differences between 
patients screened in hospitals and by ophthalmologists in 
private practice. Eighty-six percent of patients screened by 
ophthalmologists in private practice display no retinopathy, 
with minor interregional variations. Only 53% of patients 
screened in hospitals have no diabetic retinopathy, with a 
wide interregional disparity. These numbers indicate that a 
higher proportion of patients with more severe diabetes are 
being treated in hospital departments compared to private 
ophthalmological practice. 
In the Central Denmark Region, 11% of patients screened 
in hospitals have “proliferative diabetic retinopathy, newly 
diagnosed”, a significantly higher number than in other 
regions of Denmark. There is less interregional difference if 
preproliferative patients are included in this category. Even 
Table 1 indicators and standards for DiaBase
Area Indicator Standard
1. Newly diagnosed diabetes patients Proportion of diabetes patients obtaining eye screening for diabetic retinopathy and 
maculopathy within the prospective time period (12 months from diagnosis)
At least 95%
2. Frequency of diabetic eye screening Proportion of diabetes patients obtaining eye screening for diabetic retinopathy and 
maculopathy within the defined interval
At least 90%
3. Prevalence of retinopathy and 
maculopathy
Prevalence according to the stage of retinopathy and maculopathy Not set
Proportion of diabetes patients progressing to a more severe level of diabetic eye disease Not set
Proportion of diabetes patients regressing to a milder stage of diabetic eye disease Not set
4. Prevalence of blindness Proportion of patients registered as blind Not set
Abbreviation: DiaBase, Danish Registry of Diabetic Retinopathy.
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Table 2 Screening within the planned interval 
Proportion of diabetes patients obtaining eye screening for diabetic retinopathy and maculopathy within the planned interval 
(standard: at least 90%)
Geographic area/health sector Current year: March 2014–February 2015 Earlier years, %
Numerator/
denominator
Unknown, N (%) Proportion 
(95% CI)
Proportion, 
2013–2014
Proportion, 
2012–2013b
Denmark 22,962/35,440 2,565 (7) 65 (64–65) 60 64
Hospital units, total 8,493/16,002 2,305 (13) 53 (52–54) 63 64
Capital Region of Denmarka 1,212/4,842 2,065 (30) 25 (24–26) 31 42
Region Zealand 1,343/1,851 42 (2) 73 (70–75) 69 62
Region of Southern Denmark 2,473/3,711 106 (3) 67 (65–68) 87 87
Central Denmark Region 2,043/3,232 88 (3) 63 (62–65) 64 62
North Denmark Region 1,422/2,366 4 (<1) 60 (58–62) 58 66
Ophthalmological practices, total 14,469/19,438 260 (1) 74 (74–75) 45
Capital Region of Denmark 2,205/3,175 165 (5) 69 (68–71) 36
Region Zealand 454/708 16 (2) 64 (60–68) 16
Region of Southern Denmark 8,400/10,326 70 (1) 81 (81–82) 56
Central Denmark Region 2,915/4,124 8 (<1) 71 (69–72) 37
North Denmark Region 495/1,105 1 (<1) 45 (42–48) 19
Notes: Numerator: patients whose eye screening was performed within the defined interval ± ~33% of the defined interval (months to next eye screening): 3 months ± 
1 month, 6 months ± 2 months, 12 months ± 4 months, 18 months ± 6 months, 24 months ± 8 months, 48 months ± 12 months; denominator: all screening visits were 
performed in the defined period, where an earlier visit had been recorded and a planned interval defined by the ophthalmologist; unknown: number of months to next 
screening visit not disclosed. aDifferent screening strategies with longer ± tolerances compared with the other regions explain the low numbers. bData collection from 
patients screened in ophthalmological practice started in 2013 and is still being extended to cover all practices.
Abbreviation: CI, confidence interval.
Table 3 Prevalence of diabetic retinopathy (March 2014–February 2015)
Geographic region/health 
sector
Patients 
with known 
retinopathy 
status (n)
Retinopathy status
None 
(%)
Mild 
(%)
Moderate 
(%)
Preproliferative 
(%)
Proliferative, 
stable (%)
Proliferative, 
new (%)
Proliferative, 
recurrence (%)
Denmark 77,968 78 13 4 1 1 3 0
Hospital units, total 20,000 53 26 10 2 4 4 0
Capital Region of Denmark 8,216 60 29 3 1 3 4 0
Region Zealand 2,044 49 21 11 5 12 1 1
Region of Southern 
Denmark
4,028 52 17 18 5 8 0 0
Central Denmark Region 3,276 36 40 13 1 0 11 0
North Denmark Region 2,436 53 22 16 3 0 6 0
Ophthalmological practices, 
total 
57,968 86 9 2 0 0 2 0
Capital Region of Denmark 11,245 91 6 2 0 0 1 0
Region Zealand 7,210 87 9 2 0 0 2 0
Region of Southern 
Denmark
20,828 85 9 3 0 0 3 0
Central Denmark Region 12,205 84 11 2 0 0 3 0
North Denmark Region 6,480 87 9 2 0 0 1 0
though DiaBase clearly defines the criteria for classification 
of preproliferative versus proliferative diabetic retinopathy, 
regional traditions may play a role in differing interpretations. 
Sight-threatening subtypes (newly diagnosed and previously 
treated recurrent proliferative diabetic retinopathy) comprise 
3% of patients. The number of patients with recurrence after 
treatment is very small. One percent of patients are recorded 
as “laser treated and stable”.
Diabetic maculopathy is significantly more  uncommon 
than diabetic retinopathy. The overall prevalence of patients 
without diabetic maculopathy is 97% in the registry 
(91% screened in hospitals vs 98% screened by ophthal-
mologists in private practice). Only 2% of all patients have 
newly  diagnosed diabetic maculopathy, and an equally 
small number of patients have stable maculopathy after 
treatment (Table 4).
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Table 4 Prevalence of diabetic maculopathy (March 2014–February 2015)
Geographic region/health sector Patients with known 
maculopathy status (n)
Maculopathy status
None (%) Stable (%) New (%) Recurrence (%)
Denmark 74,554 97 2 2 0
Hospital units, total 19,267 91 3 6 0
Capital Region of Denmark 7,777 91 3 6 0
Region Zealand 1,824 77 11 12 1
Region of Southern Denmark 3,959 94 3 3 0
Central Denmark Region 3,292 90 0 10 0
North Denmark Region 2,415 100 0 0 0
Ophthalmological practices, total 55,287 98 1 0 0
Capital Region of Denmark 10,742 99 1 0 0
Region Zealand 6,957 98 1 0 0
Region of Southern Denmark 19,762 98 1 1 0
Central Denmark Region 11,622 98 1 0 0
North Denmark Region 6,204 99 1 0 0
Table 5 Progression of diabetic eye disease
Proportion of diabetes patients progressing to a more severe level of diabetic eye disease
Geographic area/health sector Current year: March 2014–February 2015 Earlier years, %
Numerator/
denominator
Unknown, N (%) Proportion 
(95% CI)
Proportion, 
2013–2014
Proportion, 
2012–2013a
Denmark 2,905/28,912 339 (1) 10 (10–10) 14 14
Hospital units, total 2,106/13,668 309 (2) 15 (15–16) 14 14
Capital Region of Denmark 573/4,776 284 (6) 12 (11–13) 11 12
Region Zealand 262/1,446 4 (<1) 18 (16–20) 15 13
Region of Southern Denmark 472/3,143 0 (0) 15 (14–16) 11 11
Central Denmark Region 353/2,280 21 (1) 15 (14–17) 16 16
North Denmark Region 444/2,023 0 (0) 22 (20–24) 17 17
Ophthalmological practices, total 799/15,244 30 (<1) 5 (5–6) 12
Capital Region of Denmark 121/2,460 20 (1) 5 (4–6) 9
Region Zealand 24/414 6 (1) 6 (4–9) 10
Region of Southern Denmark 417/8,346 2 (<1) 5 (5–5) 21
Central Denmark Region 202/3,383 2 (<1) 6 (5–7) 10
North Denmark Region 35/641 0 (0) 5 (4–8) 7
Notes: Numerator: patients whose poorest eye progressed to a more severe stage of diabetic eye disease since the last eye screening visit in the year before the annual 
report (higher number = more severe stage of disease): 1, none; 2, mild nonproliferative; 3, moderate nonproliferative; 4, preproliferative; 5, treated stable proliferative 
retinopathy/macular edema; 6, active proliferative retinopathy or diabetic macular edema – treated or recurrence. Denominator: all patients whose poorest eye was not 
labeled as being in the most severe stage of eye disease previous to the year of the annual report. aData collection from patients screened in ophthalmological practice started 
in 2013 and is still being extended to cover all practices.
Abbreviation: CI, confidence interval.
Progression/regression of diabetic retinopathy and 
maculopathy
Diabetic retinal changes may progress as well as regress, essen-
tially depending on medical treatment and diabetic control. The 
proportion of diabetes patients progressing to a more severe 
level of diabetic eye disease is a key  outcome measurement 
for DiaBase (Table 5). This requires at least two eye screening 
visits with retinopathy and  maculopathy grading. To calculate 
this indicator, patients with the poorest-seeing eye and in the 
most severe stage of disease at the first of the screening visits 
are excluded from the assessment. Furthermore, the proportion 
of diabetes patients regressing to a milder stage of diabetic eye 
disease is assessed (Table 6). This also requires at least two eye 
screening visits with retinopathy and maculopathy grading. To 
calculate this indicator, patients with the poorest-seeing eye 
and in the mildest stage of disease (none) at the first of the 
screening visits are excluded from the assessment.
In 2014–2015, 10% of registered patients progressed to 
a more severe stage of disease nationwide. However, this 
figure is lower than that reported during 2013–2014 (14%).9 
Five percent of patients screened by ophthalmologists in 
private practice progress to a more severe disease compared 
to 15% of patients screened in hospitals. There is a wide 
interregional variation (12%–22%) in the latter group. 
The proportion of patients regressing to a milder stage of 
disease has been analyzed for the first time in 2014–2015. 
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Eighteen percent of patients screened in hospitals regress to 
a milder stage of disease (interregional variation between 
12% and 23%). Twenty-four percent of patients screened by 
ophthalmologists in private practice regressed to a milder 
stage of disease. Nonetheless, the percentage of these patients 
is  significantly higher in the North Denmark region (58%) 
than in the other regions, where percentages vary between 
19% and 28%. This difference may be based on variations 
in grading due to region-specific circumstances.
Administrative issues and funding
DiaBase was established by N Andersen in collaboration with 
The Danish Ophthalmological Society and the Organization 
of Danish Ophthalmologists in Private Practice,13 based on 
the status screening for diabetic retinopathy in Denmark.14 
The registry is led by a steering committee of medical retina 
specialists representing the five regions of Denmark, the 
Chairman of the Danish Ophthalmological Society, and the 
Chairman of the Organization of Danish Ophthalmologists 
in Private Practice.
Initially, the register was partly funded by Hovedstadens 
Sygehusfællesskab (Association of Hospitals in the Capital 
Region of Denmark). DiaBase is funded and operated by The 
Danish Clinical Registries (RKKP), which is financed and 
owned by the five Danish regions. 
Conclusion
The systematic collection of data from diabetic eye screening 
in Denmark is still in the development process. Data analysis 
from DiaBase’s latest annual report (2014–2015)11 reveals 
a decrease in the prevalence of diabetic retinopathy from 
26% to 22% compared to the previous report (2013–2014), 
whereas the number of patients diagnosed with diabetes 
has increased between 1996 and 2012.10 Additionally, the 
proportion of patients with regression (20%) is greater than 
the proportion of patients with progression (10%) of diabetic 
retinopathy.
The DiaBase is a useful tool to observe the quality of 
screening, prevalence, and progression/regression of diabetic 
eye disease. Thus, it contributes to ensure a high quality of 
care for diabetes patients in Denmark. Reducing the overall 
morbidity and mortality associated with diabetes by prevent-
ing complications may help to relieve the large economic 
burden of the disease. 
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Table 6 Regression of diabetic eye disease
Proportion of diabetes patients regressing to a milder stage of diabetic eye disease 
Geographic area/health sector Current year: March 2014–February 2015 Earlier years, %
Numerator/
denominator
Unknown,  
N (%)
Proportion  
(95% CI)
Proportion,  
2013–2014
Proportion, 
2012–2013a
Denmark 1,558 / 7,759 339 (4) 20 (19–21) 20 18
Hospital units, total 1,040/5,622 309 (5) 18 (17–20) 19 18
Capital Region of Denmark 364/1,611 284 (15) 23 (21–25) 19 18
Region Zealand 148/742 4 (1) 20 (17–23) 18 12
Region of Southern Denmark 205/1,149 0 (0) 18 (16–20) 15 13
Central Denmark Region 174/1,474 21 (1) 12 (10–14) 15 14
North Denmark Region 149/646 0 (0) 23 (20–27) 32 37
Ophthalmological practices, total 518/2,137 30 (1) 24 (22–26) 44
Capital Region of Denmark 65/230 20 (8) 28 (23–35) 46
Region Zealand 28/111 6 (5) 25 (17–34) 27
Region of Southern Denmark 214/1,147 2 (<1) 19 (16–21) 47
Central Denmark Region 141/528 2 (<1) 27 (23–31) 42
North Denmark Region 70/121 0 (0) 58 (49–67) 60
Notes: Numerator: patients whose poorest eye regressed to a milder stage of diabetic eye disease since the last eye screening visit in the previous year; denominator: all 
patients whose poorest eye was not labeled as being in the mildest stage of disease (none) previous to the current year (2014–2015). aData collection from patients screened 
in ophthalmological practice started in 2013 and is still being extended to cover all practices.
Abbreviation: CI, confidence interval.
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